Close Menu

NEW YORK – Chembio Diagnostics reported after the close of the market on Thursday that its second-quarter revenues dropped 48 percent year over year following the revocation of the Emergency Use Authorization by the US Food and Drug Administration for the company's SARS-CoV-2 antibody test.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.